Placebo News and Research

RSS

Opicapone simplifies levodopa-related motor fluctuation treatment

Once-daily opicapone is effective for the treatment of end-of-dose motor fluctuations in patients receiving levodopa for Parkinson’s disease, phase III study findings show.

23 Dec 2015

Add-on lamotrigine enhances bipolar depression treatment

Combining lamotrigine with quetiapine improves the treatment of depressive symptoms in patients with bipolar disorder, with the benefits maintained for at least a year, show findings from the CEQUEL trial.

23 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

Pauses and reversals ‘not uncommon’ in ALS progression

Patients with amyotrophic lateral sclerosis often have periods of stable disease, with some even experiencing brief improvements, shows analysis of the PRO-ACT database.

18 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Men perform wayfinding tasks better than women

It's been well established that men perform better than women when it comes to specific spatial tasks. But how much of that is linked to sex hormones versus cultural conditioning and other factors? Researchers at the Norwegian University of Science and Technology (NTNU) decided to explore this idea by administering testosterone to women and testing how they performed in wayfinding tasks in a virtual environment.

17 Dec 2015

New study suggests that musclin may promote muscle health

A new study in mice shows that exercise causes muscle to release a peptide that builds the muscle's capacity for energy production and increases physical endurance, allowing for longer and more intense exercise.

17 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015

New study examines antioxidant effects of pomegranate extract on cardiovascular risk factors

A new study assessing the antioxidant effects of pomegranate extract on cardiovascular risk factors and muscle function showed reductions in blood pressure and some atheroprotective benefits, but no effects on inflammation, oxidative strength, or muscle strength.

15 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty.

12 Dec 2015

Early promise for pulmonary artery denervation in PAH patients

Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.

11 Dec 2015

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).

11 Dec 2015

Placebo News and Research

Opicapone simplifies levodopa-related motor fluctuation treatment

Add-on lamotrigine enhances bipolar depression treatment

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Pauses and reversals ‘not uncommon’ in ALS progression

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Men perform wayfinding tasks better than women

New study suggests that musclin may promote muscle health

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

New study examines antioxidant effects of pomegranate extract on cardiovascular risk factors

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Early promise for pulmonary artery denervation in PAH patients

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News